Dogwood Therapeutics, Inc. (DWTX) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.04

From 52W high−84.97%

Volume120704.00

Market cap$34.84M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$1.04

From 52W high

−84.97%

Volume

120704.00

Market cap

$34.84M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.9x

P/E (TTM)

—

RSI (14)

32.1

MomentumView details →

1D Return

−1.44%

YTD Return

−74.49%

SummaryUpdated Jun 1, 2026

Dogwood Therapeutics, Inc. (NASDAQ:DWTX) is a development-stage biotechnology company founded in 2012 and headquartered in Alpharetta, Georgia. The company was formerly known as Virios Therapeutics, Inc. before changing its name to Dogwood Therapeutics in October 2024. As a clinical-stage biotech firm, Dogwood focuses on developing novel antiviral therapies designed to treat diseases associated with viral-triggered abnormal immune responses, representing a specialized approach within the broader biotechnology industry.

Ask drillr about Dogwood Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−52.72%

ROA (TTM)

−44.77%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+51.33%

FCF YoY

+4.08%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+65.50%

EBITDA YoY

−20.91%

MomentumView details →

1D Return

−1.44%

YTD Return

−74.49%

1Y Return

−80.91%

RSI (14)

32.1

vs 50D SMA

−33.36%

vs 200D SMA

−45.62%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

3.89x

Quick Ratio

3.89x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.34

EPS Surprise

−142.86%

Beats (12Q)

5/12

Next Q EPS Est

−$0.16

Avg Surprise (4Q)

−183.91%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−36.04M

Op. CF (TTM)

−15.11M

Next earningsNov 5, 2026 →

Latest newsMore news →

Dogwood Therapeutics entered into a registration rights agreement with Sealbond Limited covering resale registration of the shares issued in the private placement.16d ago

Dogwood Therapeutics agreed to sell 4,098,360 common shares to Sealbond Limited in a private placement for $1.22 per share, totaling $4,999,999.20, for general working capital.16d ago

Similar companies

EyePoint Pharmaceuticals, Inc.EYPT Elutia Inc.ELUT Lite Strategy, Inc.LITS Veru Inc.VERU Quince Therapeutics, Inc.QNCX Quince Therapeutics, Inc.IRLA Find similar companies →

Latest newsMore news →

Dogwood Therapeutics entered into a registration rights agreement with Sealbond Limited covering resale registration of the shares issued in the private placement.16d ago Dogwood Therapeutics agreed to sell 4,098,360 common shares to Sealbond Limited in a private placement for $1.22 per share, totaling $4,999,999.20, for general working capital.16d ago Dogwood Therapeutics completed patient enrollment in its ongoing Phase 2b trial of Halneuron for chemotherapy-induced neuropathic pain, enrolling 239 patients.51d ago